Inhaled peptides and proteins show great promise for respiratory and systemic disease treatment. This class of molecules is particularly well suited to formulation and processing by spray-drying to achieve respirable engineered particles. This webinar describes formulation and process development for a novel inhaled biotherapeutic, an insulin dry-powder inhalation (DPI) formulation, as well as important preclinical in vivo modeling methodologies required to understand biologic performance. The performance of the novel spray-dried powder is compared to that of Exubera™.
Please note that Lonza has updated its Privacy Policy. By visiting our website or using services provided by Lonza, you are accepting the practices described in the Privacy Policy.
We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. Please read our updated Cookies Policy for information about which cookies we use and the information we collect. By continuing to use this website, you agree that we may store and access cookies on your device.
By clicking "I Agree", you confirm that you are above the age of 16, that you have read and understood the Privacy Policy and the Cookies Policy, and that you agree to the collection, use and processing of your Personal Information by Lonza in accordance with said policies.